
June 24 (Reuters) - Nektar Therapeutics NKTR.O:
REZOLVE-AD PHASE 2B STUDY OF REZPEGALDESLEUKIN MEETS PRIMARY AND KEY SECONDARY ENDPOINTS IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS
NEKTAR THERAPEUTICS - REZOLVE-AD PHASE 2B STUDY MEETS PRIMARY AND KEY SECONDARY ENDPOINTS
NEKTAR THERAPEUTICS - ACHIEVED STATISTICAL SIGNIFICANCE ON PRIMARY ENDPOINT AT WEEK 16
NEKTAR THERAPEUTICS - SAFETY PROFILE CONSISTENT WITH PREVIOUSLY REPORTED RESULTS
NEKTAR THERAPEUTICS: DATA EXPECTED IN Q1 2026 FROM TREATMENT OF PATIENTS WITH ATOPIC DERMATITIS IN LONG-TERM MAINTENANCE PART OF REZOLVE-AD STUDY
NEKTAR THERAPEUTICS -TOP-LINE PHASE 2B DATA FOR REZPEGALDESLEUKIN IN ALOPECIA AREATA EXPECTED IN Q4 2025